U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Myelofibrosis due to another disorder

MedGen UID:
116127
•Concept ID:
C0242006
•
Disease or Syndrome
Synonyms: Secondary myelofibrosis; Secondary Myelofibrosis
SNOMED CT: Myelofibrosis due to another disorder (119031000119101); Secondary myelofibrosis (119031000119101)

Definition

Myelofibrosis that develops in patients with a history of hematologic malignancies or toxic injury to the bone marrow. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVMyelofibrosis due to another disorder

Professional guidelines

PubMed

Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol 2023 May;98(5):801-821. Epub 2023 Feb 6 doi: 10.1002/ajh.26857. PMID: 36680511
Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
Tefferi A
Am J Hematol 2021 Jan;96(1):145-162. Epub 2020 Dec 2 doi: 10.1002/ajh.26050. PMID: 33197049
Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
Tefferi A, Barbui T
Am J Hematol 2020 Dec;95(12):1599-1613. Epub 2020 Oct 23 doi: 10.1002/ajh.26008. PMID: 32974939

Recent clinical studies

Etiology

Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol 2023 May;98(5):801-821. Epub 2023 Feb 6 doi: 10.1002/ajh.26857. PMID: 36680511
Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives.
Baumeister J, Chatain N, Sofias AM, Lammers T, Koschmieder S
Cells 2021 Dec 16;10(12) doi: 10.3390/cells10123551. PMID: 34944059Free PMC Article
Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
Tefferi A
Am J Hematol 2021 Jan;96(1):145-162. Epub 2020 Dec 2 doi: 10.1002/ajh.26050. PMID: 33197049
A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management.
Garmezy B, Schaefer JK, Mercer J, Talpaz M
Blood Rev 2021 Jan;45:100691. Epub 2020 Apr 7 doi: 10.1016/j.blre.2020.100691. PMID: 32354563
Myelofibrosis biology and contemporary management.
Gangat N, Tefferi A
Br J Haematol 2020 Oct;191(2):152-170. Epub 2020 Mar 20 doi: 10.1111/bjh.16576. PMID: 32196650

Diagnosis

Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol 2023 May;98(5):801-821. Epub 2023 Feb 6 doi: 10.1002/ajh.26857. PMID: 36680511
Myelofibrosis.
Passamonti F, Mora B
Blood 2023 Apr 20;141(16):1954-1970. doi: 10.1182/blood.2022017423. PMID: 36416738
Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms.
Fisher DAC, Fowles JS, Zhou A, Oh ST
Front Immunol 2021;12:683401. Epub 2021 Jun 1 doi: 10.3389/fimmu.2021.683401. PMID: 34140953Free PMC Article
Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
Tefferi A
Am J Hematol 2021 Jan;96(1):145-162. Epub 2020 Dec 2 doi: 10.1002/ajh.26050. PMID: 33197049
A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management.
Garmezy B, Schaefer JK, Mercer J, Talpaz M
Blood Rev 2021 Jan;45:100691. Epub 2020 Apr 7 doi: 10.1016/j.blre.2020.100691. PMID: 32354563

Therapy

Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol 2023 May;98(5):801-821. Epub 2023 Feb 6 doi: 10.1002/ajh.26857. PMID: 36680511
Myelofibrosis.
Passamonti F, Mora B
Blood 2023 Apr 20;141(16):1954-1970. doi: 10.1182/blood.2022017423. PMID: 36416738
Anemia in myelofibrosis: Current and emerging treatment options.
Passamonti F, Harrison CN, Mesa RA, Kiladjian JJ, Vannucchi AM, Verstovsek S
Crit Rev Oncol Hematol 2022 Dec;180:103862. Epub 2022 Nov 1 doi: 10.1016/j.critrevonc.2022.103862. PMID: 36332787
Next Generation Therapeutics for the Treatment of Myelofibrosis.
Tremblay D, Mascarenhas J
Cells 2021 Apr 27;10(5) doi: 10.3390/cells10051034. PMID: 33925695Free PMC Article
Management of myelofibrosis after ruxolitinib failure.
Harrison CN, Schaap N, Mesa RA
Ann Hematol 2020 Jun;99(6):1177-1191. Epub 2020 Mar 20 doi: 10.1007/s00277-020-04002-9. PMID: 32198525Free PMC Article

Prognosis

Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol 2023 May;98(5):801-821. Epub 2023 Feb 6 doi: 10.1002/ajh.26857. PMID: 36680511
Myelofibrosis.
Passamonti F, Mora B
Blood 2023 Apr 20;141(16):1954-1970. doi: 10.1182/blood.2022017423. PMID: 36416738
Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
Tefferi A
Am J Hematol 2021 Jan;96(1):145-162. Epub 2020 Dec 2 doi: 10.1002/ajh.26050. PMID: 33197049
A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management.
Garmezy B, Schaefer JK, Mercer J, Talpaz M
Blood Rev 2021 Jan;45:100691. Epub 2020 Apr 7 doi: 10.1016/j.blre.2020.100691. PMID: 32354563
Myelofibrosis biology and contemporary management.
Gangat N, Tefferi A
Br J Haematol 2020 Oct;191(2):152-170. Epub 2020 Mar 20 doi: 10.1111/bjh.16576. PMID: 32196650

Clinical prediction guides

Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol 2023 May;98(5):801-821. Epub 2023 Feb 6 doi: 10.1002/ajh.26857. PMID: 36680511
Myelofibrosis.
Passamonti F, Mora B
Blood 2023 Apr 20;141(16):1954-1970. doi: 10.1182/blood.2022017423. PMID: 36416738
Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms.
Fisher DAC, Fowles JS, Zhou A, Oh ST
Front Immunol 2021;12:683401. Epub 2021 Jun 1 doi: 10.3389/fimmu.2021.683401. PMID: 34140953Free PMC Article
Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
Tefferi A
Am J Hematol 2021 Jan;96(1):145-162. Epub 2020 Dec 2 doi: 10.1002/ajh.26050. PMID: 33197049
Myelofibrosis biology and contemporary management.
Gangat N, Tefferi A
Br J Haematol 2020 Oct;191(2):152-170. Epub 2020 Mar 20 doi: 10.1111/bjh.16576. PMID: 32196650

Recent systematic reviews

Management of Myeloproliferative Neoplasms (MPNs).
Nurgat Z, Lawrence M
J Oncol Pharm Pract 2022 Sep;28(6):1400-1410. Epub 2022 Mar 16 doi: 10.1177/10781552221082293. PMID: 35296179
Interferon Therapy in Myelofibrosis: Systematic Review and Meta-analysis.
Bewersdorf JP, Giri S, Wang R, Podoltsev N, Williams RT, Rampal RK, Tallman MS, Zeidan AM, Stahl M
Clin Lymphoma Myeloma Leuk 2020 Oct;20(10):e712-e723. Epub 2020 May 28 doi: 10.1016/j.clml.2020.05.018. PMID: 32669244Free PMC Article
Splenic irradiation for splenomegaly: A systematic review.
Zaorsky NG, Williams GR, Barta SK, Esnaola NF, Kropf PL, Hayes SB, Meyer JE
Cancer Treat Rev 2017 Feb;53:47-52. Epub 2016 Dec 22 doi: 10.1016/j.ctrv.2016.11.016. PMID: 28063304Free PMC Article
How common are myeloproliferative neoplasms? A systematic review and meta-analysis.
Titmarsh GJ, Duncombe AS, McMullin MF, O'Rorke M, Mesa R, De Vocht F, Horan S, Fritschi L, Clarke M, Anderson LA
Am J Hematol 2014 Jun;89(6):581-7. doi: 10.1002/ajh.23690. PMID: 24971434
Extramedullary hemopoiesis.
Orphanidou-Vlachou E, Tziakouri-Shiakalli C, Georgiades CS
Semin Ultrasound CT MR 2014 Jun;35(3):255-62. Epub 2013 Dec 19 doi: 10.1053/j.sult.2013.12.001. PMID: 24929265

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...